ClinicalTrials.gg
Enrolling by invitationNCT07410403AIUpdated Feb 13, 2026

AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities

An observational study in Multiple Myeloma, sponsored by Fuling Zhou. Enrolling by invitation at 1 site in China. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Fuling Zhou · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
10
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
41st of 41
10 · median 210
Started
2018
with 20 others
Observational
41 of 448
28 open now
Primary completion
2026-12
later than 110 of 274 live
Registered
360th of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 41st largest by planned enrollment of the 41 observational ones that give a count, is one of 21 that started in 2018, is one of 41 observational ones, reaches primary completion later than 110 of the 274 other live ones, and was the 360th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

This study developed an artificial intelligence (AI)-based methodology for the quantitative analysis of single-cell morphological data in multiple myeloma (MM). The approach achieves high-precision AI-driven identification and segmentation of myeloma cells, nuclei, cytoplasm, and nucleoli, overcoming the inherent limitations of subjective traditional morphological analysis.

Furthermore, integrating this morphological quantification with cytogenetic abnormality analysis of myeloma cells provides an efficient predictive tool for identifying high-risk cytogenetic abnormalities.

Leveraging AI-guided selection of genetic testing targets, the research applied a rapid genetic abnormality detection technique utilizing first-drop bone marrow aspirate smears. This methodology achieves orders of magnitude improvements in testing cost, sample preprocessing time and detection sensitivity.

Read the detailed description

Multiple myeloma (MM) is a malignant plasma cell disorder exhibiting a rising global incidence associated with population aging. The significant intraclonal heterogeneity and complexity of clonal evolution inherent in MM genetics contribute to profound inter-individual heterogeneity. This complicates precise prognostic stratification and disease management, rendering MM largely incurable even in the era of novel therapies. In early-stage MM, primary cytogenetic abnormalities predominantly include odd-numbered chromosome trisomies and immunoglobulin heavy chain gene (IGH) rearrangements, such as t(11;14) and t(4;14). Disease progression and terminal stages are frequently characterized by the acquisition of increasingly complex copy number alterations (CNAs) (e.g., 1q gain/amplification [1q+] and 17p deletion [17p-]) and MYC rearrangements. These secondary events further drive cellular proliferation and tumor growth, collectively contributing to MM's high aggressiveness and therapeutic resistance.

Fluorescence in situ hybridization (FISH), particularly when combined with CD138 immunomagnetic bead sorting for plasma cell enrichment, plays a pivotal role in enhancing the detection rate of cytogenetic abnormalities in MM. However, a comprehensive MM genetic assessment necessitates the selection of multiple FISH probes targeting diverse genetic events, including several associated with high-risk progression. This requirement introduces significant complexity in probe selection. The Mayo Clinic utilizes an initial FISH screening panel for newly diagnosed MM targeting loci on chromosomes 1, 3, 7, 8, 9, 11, 13, 14, 15, and 17. Based on the results from the IGH break-apart probe on chromosome 14 (identifying an IGH break in approximately 50% of NDMM cases), positive cases undergo additional FISH testing for specific translocations: t(4;14), t(6;14), t(14;16), and t(14;20). Nevertheless, implementing such a comprehensive FISH approach is often hindered by the large number of required targets, limited plasma cell yields after bead enrichment/purification, and potential FISH assay failure.

While FISH is crucial for detecting MM cytogenetic abnormalities, current National Comprehensive Cancer Network (NCCN) guidelines highlight up to seven specific high-risk cytogenetic abnormalities associated with progression/relapse in NDMM: 1q21 gain (1q21+), 1p32 deletion (1p32-), del(17p)/monosomy 17 (-17)/TP53 mutation, t(4;14), t(14;16), t(14;20), and MYC rearrangement. The practical clinical application and accuracy of FISH are frequently limited by the extensive number of targets required for a complete assessment and the variability/complexity of standard FISH methodologies. An initial FISH screen must include an IGH break-apart probe. Subsequent testing with specific fusion probes for t(11;14), t(4;14), t(6;14), t(14;16), and t(14;20) is performed only if the IGH break-apart probe is positive.

Previous studies have reported on prognostic significance based on expert morphological classification of myeloma cells into plasmablastic, immature, and mature plasma cell types. However, utilizing myeloma cell morphology to predict specific FISH-detectable cytogenetic abnormalities remains unexplored. Artificial intelligence (AI) has demonstrated growing applications in medical image recognition and classification, including high-precision identification of leukemia, lymphoma, and MM cells. Recent research reported AI's ability to identify four specific acute leukemia molecular subtypes (PML::RARA fusion-positive; NPM1-mutated; CBFB::MYH11 fusion-positive without NPM1 mutation; RUNX1::RUNX1T1 fusion-positive) based on leukemia cell morphology in peripheral blood smears. Yet, analogous studies predicting cytogenetic abnormalities from MM cell morphology are currently lacking.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • artificial intelligence
  • myeloma
  • genetic
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

according to the criteria outlined in the Chinese guidelines for MM diagnosis and management (2024 edition)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • according to the criteria outlined in the Chinese guidelines for MM diagnosis and management (2024 edition)

Exclusion criteria

Exclusion Criteria:

  • non-MM
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
10 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • myeloma

    high-precision AI-driven identification and segmentation of myeloma cells, nuclei, cytoplasm, and nucleoli, overcoming the inherent limitations of subjective traditional morphological analysis

06

What researchers measure

Primary outcomes

  1. Cytogenetic result of multiple myeloma

    To predict cytogenetic result of multiple myeloma, using high-precision AI-driven identification and segmentation of myeloma cells, nuclei, cytoplasm, and nucleoli.

    Time frame: 2 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2018 (actual). Primary completion is estimated for Dec 2026, 100 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Feb 13, 2026
StartActual
Aug 1, 2018
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07410403
Lead sponsor
Fuling Zhou
Collaborators
Wuhan Central Hospital, The Affiliated Hospital Of Southwest Medical University, Linyi People's Hospital
Responsible party
Fuling Zhou (Professor, Zhongnan Hospital) — Sponsor-investigator
First posted
Feb 13, 2026
Start date
Aug 1, 2018
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion